<DOC>
	<DOCNO>NCT01710995</DOCNO>
	<brief_summary>The purpose study assess effectiveness Zegerid 20mg capsule powder Losec 20mg capsule healthy volunteer fast condition .</brief_summary>
	<brief_title>A Three-Period Study Investigate Relative Bioavailability Pharmacodynamic Profiles Zegerid 20mg Capsule , Zegerid 20mg Powder Oral Suspension Losec 20mg Capsule Healthy Adult Volunteers Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Omeprazole , sodium bicarbonate drug combination</mesh_term>
	<criteria>Healthy adult male female volunteer age 18 45 year . Nonsmokers three month receive first dose duration study , confirm negative urinary cotinine test screening checkin . Body mass index ( BMI ) ≥ 18.0 ≤ 27.9 kg/m2 . Able voluntarily provide write informed consent participate study . Must understand purpose risk study agree follow restriction schedule procedure define protocol . Able willing nasogastric tube/probe insert . Females must postmenopausal ( least one year confirm serum FSH screening ) , surgically sterile , practice true sexual abstinence use acceptable form effective contraception throughout study follow list : contraceptive implant , injectables , oral contraceptive , intrauterine system ( IUS ) , intrauterine device ( IUDs ) , vasectomise partner barrier method ( condom occlusive cap ) spermicidal foam/gel/film/cream/suppository . Hormonal IUD method contraception must establish period three month prior dose change altered study . Females childbearing potential must negative pregnancy test screening checkin . Must willing consent data enter The Over Volunteering Prevention System ( TOPS ) . The volunteer 's primary care physician must confirm nothing medical history would preclude enrolment clinical study . Positive HIV , hepatitis B hepatitis C. History presence significant cardiovascular , pulmonary , hepatic , renal , haematological , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease determine Investigator . History gastric duodenal ulcer . History hiatus hernia . Significant history reflux symptom clinical judgement . Diagnosis condition likely result hypersecretory gastric acid state e.g . ZollingerEllison Syndrome . Positive serology test result H. pylorus screen . Clinically significant deviate nasal septum nasopharyngeal obstruction , inability tolerate site nasogastric tube screening . Hypersensitivity contraindication Zegerid® Losec® . History presence clinically significant drug allergy . Female subject pregnant lactating . Laboratory value screen deem clinically significant determine Investigator . Any clinically relevant history drug alcohol abuse . Volunteers , opinion Investigator , unsuitable participation study . Participation clinical drug study 90 day precede initial dose study medication . Any significant illness screen period precede initial dose study medication . Donation blood blood product within 90 day prior study drug administration , time study , except require protocol . Consumption alcoholic beverage xanthinecontaining product within 24 hour confinement study confinement . Consumption cruciferous vegetable chargrilled food within 48 hour confinement study confinement . Consumption grapefruit grapefruit juice seven day confinement end study . Use prescription overthecounter medication ( include vitamin , herbal mineral supplement ) within 30 day study drug administration , general anaesthetic three month study drug administration , end study , exception Investigatorapproved hormonal contraceptive , HRT occasional paracetamol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>